Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-03-13
DOI
10.1111/1346-8138.14834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relationship between environmental factors, age of onset and familial history in Japanese patients with psoriasis
- (2018) Bolortuya Bayaraa et al. JOURNAL OF DERMATOLOGY
- The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis
- (2018) Alice B. Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis
- (2017) Eric Toussirot EXPERT OPINION ON BIOLOGICAL THERAPY
- Switching of biologics in psoriasis: Reasons and results
- (2017) Hiromi Honda et al. JOURNAL OF DERMATOLOGY
- Biologic treatments for elderly patients with psoriasis
- (2017) Mami Momose et al. JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
- (2017) Désirée van der Heijde et al. JOURNAL OF RHEUMATOLOGY
- Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
- (2017) C. Dressler et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
- (2017) A. Nast et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
- (2017) Jillian Frieder et al. Therapeutic Advances in Chronic Disease
- Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
- (2016) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Distinguishing features of body mass index and psoriasis in men and women in Japan: A hospital-based case-control study
- (2016) Reiko Naito et al. JOURNAL OF DERMATOLOGY
- Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis
- (2016) Trang T. Vu et al. Expert Review of Clinical Pharmacology
- Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls
- (2015) Juul M.P.A. van den Reek et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
- (2014) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Japanese guidance for use of biologics for psoriasis (the 2013 version)
- (2013) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics
- (2013) Laura C. Coates et al. RHEUMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started